Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etofenamate→

Etofenamate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
30544-47-9
Molecular formula
C18H18F3NO4
Molecular weight
369.33 g/mol
Drug class
Topical non-steroidal anti-inflammatory drug (NSAID)fenamate derivative
Mechanism of action
A lipophilic prodrug that penetrates skin and is metabolised to flufenamic acid and related active metabolites, inhibiting cyclo-oxygenase/prostaglandin synthesis and reducing local inflammation and pain.
Indications / reported uses
  • Topical symptomatic treatment of pain and inflammation associated with acute blunt injuries such as sprains, strains and contusions, and local soft-tissue rheumatic conditions, depending on the authorised formulation

Sources: UK SmPC search — Etofenamate topical preparations · PubMed pharmacology search — Etofenamate and flufenamic acid · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Etofenamate Environmental Risk Assessment (ERA) (the Etofenamate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.